New drug targets KRAS cancers in early human trial
Disease control
Recruiting now
This early-phase study tests a new drug called ABO2102, alone or with another drug, in about 101 adults with advanced solid tumors that have a KRAS mutation. The main goals are to check safety, how the body handles the drug, and whether it shrinks tumors. This is a first-in-human…
Phase: PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC